ASX

NOVONIX Announces Resignation of Daniel Akerson from Board of Directors

Retrieved on: 
Tuesday, December 19, 2023

BRISBANE, Australia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that Daniel Akerson has resigned from the Company’s Board of Directors effective December 20, 2023.

Key Points: 
  • BRISBANE, Australia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that Daniel Akerson has resigned from the Company’s Board of Directors effective December 20, 2023.
  • Mr. Akerson cited personal reasons for his departure from the Company’s board.
  • Mr. Akerson has been a strong contributor to NOVONIX’s Board of Directors since 2022, bringing valuable expertise and strategic insights to the organization.
  • “We are grateful for Mr. Akerson’s service and contributions to the Company over his term,” said Chairman Robert J. Natter.

Opthea Receives A$8.8 million R&D Tax Incentive

Retrieved on: 
Tuesday, December 19, 2023

MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office.

Key Points: 
  • MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office.
  • The R&D tax incentive credit relates to both Australian and eligible overseas expenditure for the development of Opthea’s lead candidate OPT-302.
  • The R&D Tax Incentive is as an Australian Federal Government program under which companies can receive cash incentives for 43.5% of eligible research and development expenditure.
  • Fred Guerard, CEO of Opthea, commented, “The receipt of this A$8.8 million R&D tax incentive credit further strengthens our cash position as Opthea continues to advance its Phase 3 registrational trials, ShORe and COAST, investigating OPT-302 to address the unmet medical need in wet AMD.”

Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Retrieved on: 
Tuesday, December 19, 2023

SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development (R&D) applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.

Key Points: 
  • SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development (R&D) applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.
  • “This development is a further endorsement of the Company’s growth potential and secures our caveat-free R&D funding long-term.”
    The Finding is one of the largest awarded in Australian history as a pillar of the R&D Tax Incentive Program administered by the Australian government.
  • This Finding does not constitute a grant or an upfront payment of the amount awarded.
  • The Australian Government extends the R&D cash rebate to the Company, capturing its local and overseas R&D activities for three years (July 1, 2022 – June 30, 2025).

Strategic Joint Venture With Global Lithium Producer SQM

Retrieved on: 
Monday, December 18, 2023

The Harding Battery Metals Joint Venture tenements are adjacent to or in the vicinity of Azure Minerals’ Andover Lithium – Nickel Project where Azure announced pegmatites hosting significant widths of visible spodumene with high lithium grades returned1.

Key Points: 
  • The Harding Battery Metals Joint Venture tenements are adjacent to or in the vicinity of Azure Minerals’ Andover Lithium – Nickel Project where Azure announced pegmatites hosting significant widths of visible spodumene with high lithium grades returned1.
  • Under the option, SQM will have a 12-month period to elect to include additional Novo Pilbara tenements in the joint venture on the same terms for no further consideration.
  • The Harding Battery Metals Joint Venture expands Novo’s existing exposure to lithium exploration which includes the Quartz Hill Joint Venture with Liatam Mining near Nullagine in the East Pilbara.
  • Novo and SQM have entered into a joint venture agreement relating to Novo’s West Pilbara battery metals portfolio where SQM will be the manager HBMJV.

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea

Retrieved on: 
Monday, December 18, 2023

“The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • After three days, the mice treated with R327 showed an approximate 4-log (99.99%) reduction in bacterial shedding, demonstrating significant bactericidal activity.
  • After five days of treatment, R327 showed a 3.5-log (>99.9%) reduction in bacterial shedding compared to the placebo-treated group.
  • A late-stage preclinical study comparing IV administration to a topical application of R327 against N. gonorrhoeae is underway.

Euro Manganese Reports Fourth Quarter and Year-End 2023 Financial Results and Project Developments

Retrieved on: 
Thursday, December 14, 2023

VANCOUVER, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce key developments during the fourth fiscal quarter 2023 and to date.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce key developments during the fourth fiscal quarter 2023 and to date.
  • The Company has now filed its September 30, 2023 year-end Financial Statements, Management’s Discussion and Analysis, and other financial reports.
  • US$100 million non-dilutive funding package announced to advance development of the Chvaletice Manganese Project (the "Project"); US$20 million received on closing.
  • The Chvaletice Project received high-level inter-governmental support during the fourth calendar quarter by being named as a project under the Minerals Security Partnership.

Continued Exceptional Drilling Results at Halleck Creek

Retrieved on: 
Thursday, December 14, 2023

DENVER, Dec. 14, 2023 (GLOBE NEWSWIRE) -- American Rare Earths Limited (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF) (“ARR” or the “Company”) is pleased to announce continued exceptional drilling results from its October-November 2023 drilling campaign1,2 at Overton Mountain, located within the broader Halleck Creek Rare Earths project area. See Figure 1. Of the fifteen-reverse circulation (RC) holes drilled, there was an average TREO value 24% higher than that of the Company’s previous JORC resource estimate3 (3,309 ppm TREO). Nine of the fifteen RC holes exhibit an average TREO value of greater than 4,000 ppm, utilizing a cutoff value of 1,500 ppm. The addition of the final RC assays will be a significant contribution to upgrading the Company’s current 1.43 billion tonne JORC resource. The fence diagrams presented herein illustrate the homogenous nature of the deposit which lends itself to low-cost, near-zero strip ratio mining operations. See Figure 2.

Key Points: 
  • DENVER, Dec. 14, 2023 (GLOBE NEWSWIRE) -- American Rare Earths Limited (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF) (“ARR” or the “Company”) is pleased to announce continued exceptional drilling results from its October-November 2023 drilling campaign1,2 at Overton Mountain, located within the broader Halleck Creek Rare Earths project area.
  • Nine of the fifteen RC holes exhibit an average TREO value of greater than 4,000 ppm, utilizing a cutoff value of 1,500 ppm.
  • CEO Donald Swartz commented on the results:
    “Exceptional results from the recent resource upgrade drilling campaign at the Halleck Creek Resource Area have not only surpassed our expectations, but are expected to exceed our previous resource estimates.
  • HC23-OM044 is the most impressive RC hole, exhibiting the best intercept observed at the Halleck Creek to date.

5E Advanced Materials to Hold Stockholder Call December 19, 2023

Retrieved on: 
Tuesday, December 12, 2023

For those participants wishing to dial into the call, a participant dial-in is also available at: Dial-In: 877-407-0989 / +1 201-389-0921.

Key Points: 
  • For those participants wishing to dial into the call, a participant dial-in is also available at: Dial-In: 877-407-0989 / +1 201-389-0921.
  • A replay of the webcast will be available on the Company’s Investor Relations section of its website.
  • This communication may be deemed to be solicitation material in respect of the Transactions and certain stockholder approvals required thereby.
  • In addition, stockholders may obtain free copies of the proxy statement and other relevant materials by directing a request to: 5E Advanced Materials, Inc., 9329 Mariposa Road, Suite 210, Hesperia, CA 92344.

Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change

Retrieved on: 
Tuesday, December 12, 2023

MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect:

Key Points: 
  • MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect:
    (ii) a change of ratio in the Company’s American Depositary Share (“ADS”) program, comprising a change in the ratio of American Depositary Shares (the “ADSs”) to Shares from one (1) ADS representing six hundred (600) Shares, to one (1) ADS representing thirty (30) Shares (the “Ratio Change”).
  • The effective date of the Local Consolidation and Ratio Change (the “Effective Date”) is expected to be December 14, 2023.
  • The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol “GENE”.
  • A cancellation fee of $0.022200 per Old ADS surrendered will be charged.

Euro Manganese Welcomes New €3 Billion Fund Proposed by the European Commission to Boost Growth of the EU Battery Industry

Retrieved on: 
Monday, December 11, 2023

Euro Manganese especially supports the approach for a dedicated budget which will prioritise the best performers in sustainability, traceability, and circularity.

Key Points: 
  • Euro Manganese especially supports the approach for a dedicated budget which will prioritise the best performers in sustainability, traceability, and circularity.
  • Starting in 2024, up to €3 billion in funding is proposed to be provided via the Commission’s Innovation Fund to incentivize investment in the European Union’s ("EU") battery manufacturing capacity.
  • Commenting on the news, the European Battery Alliance ("EBA250") specifically highlighted the need for EU incentives for upstream raw materials.
  • Dr. Matthew James, President & CEO of Euro Manganese, commented:
    “Euro Manganese welcomes this recent proposal from the European Commission, which will support EU battery supply chains, including upstream sustainable raw material and refining production in the EU.